Specific Factors Identify Patients at Risk for Disease Progression in SSc Clinical Trials
Researchers identified predictive factors associated with mortality and worsening of organ function in diffuse systemic sclerosis.
Scleroderma
Skin Improvement Parallels Early Diffuse Cutaneous SSc Improvement
Disease improvement parallels skin improvement in early dcSSc — this is important for prognosis, and reflects the value of mRSS as an outcome measure in trials.
Abatacept Well-Tolerated But Has Minimal Benefit in Diffuse Cutaneous Systemic Sclerosis
Researchers assessed the safety and efficacy of abatacept in patients with diffuse cutaneous systemic sclerosis (dcSSc).
Validating REVEAL: Can Scores Accurately Predict Survival in SSc-PAH?
Researchers sought to determine the benefits of using a prognostic equation and risk score calculator to predict survival in systemic sclerosis-associated PAH.
Validating REVEAL: Can Scores Accurately Predict Survival in SSc-PAH?
Researchers sought to determine the benefits of using a prognostic equation and risk score calculator to predict survival in systemic sclerosis-associated PAH.
SSc-PAH Risk Category Improves With Ambrisentan and Tadalafil Combination Therapy
Combination treatment with ambrisentan and tadalafil is associated with a reduced mortality risk profile in patients with scleroderma-associated pulmonary arterial hypertension.
Red Cell Distribution Width May Be a Biomarker for Early Pulmonary Hypertension in SSc
Red cell distribution width may help detect early incident PH in patients who are at high risk for PH development.
Progressive Skin Fibrosis in SSc Associated With Lung Function Decline
In patients with diffuse cutaneous systemic sclerosis, developing progressive skin fibrosis within 1 year is associated with a decline in lung function and worse survival.
Rituximab Safe, Effective in Patients With Systemic Sclerosis
Rituximab treatment improved skin fibrosis in a cohort of patients with SSc, but no significant change was observed in lung fibrosis.
SSc-PAH Survival Improves With Combination Sequential Therapy
Patients with systemic sclerosis-associated pulmonary arterial hypertension who were given combination sequential therapy had improved survival rates compared with patients receiving upfront combination or monotherapy.
Next post in Scleroderma
